帕西他沙 | 87549-36-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 帕西他沙
• 中文别名: N-{4-[(2-甲基-4-氧代-4H-1,3-苯并二氧杂环己-2-基)氧基]苯基}乙酰胺
• 英文名称: (R,S)-2-(4-acetamidophenoxy)-2-methyl-4H-1,3-benzodioxin-4-one
• 英文别名: Parcetasal；N-[4-[(2-methyl-4-oxo-1,3-benzodioxin-2-yl)oxy]phenyl]acetamide
• CAS: 87549-36-8
• 化学式: C₁₇H₁₅NO₅
• 分子量: 313.31
• InChiKey: ZAPRLADYRFPQSH-UHFFFAOYSA-N

物化性质

• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  73.9
• 氢给体数：
  1
• 氢受体数：
  5

制备方法与用途

生物活性

Paclitaxel（MR-897）是一种非甾体类抗炎镇痛药物。

反应信息

• 作为产物：
  描述：

  对乙酰氨基酚 、 阿司匹林 在 三氟乙酸酐 作用下， 生成 帕西他沙
  参考文献：
  名称：

  Fallborg, Lise; Senning, Alexander, Acta Chemica Scandinavica, 1993, vol. 47, # 5, p. 514 - 520

  摘要：

  DOI：

文献信息

• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
  申请人：Griffin John

  公开号：US20060084695A1

  公开（公告）日：2006-04-20

  The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38α MAP kinase and/or HMG-CoA reductase, as well as providing formulations and modes of administering such compositions. The invention further provides methods for the rational design of inhibitors of MAP kinase, HMG-CoA reductase, or both for use in the practice of the present invention.

  本发明提供了物质组成、试剂盒和使用它们治疗MAP激酶相关疾病和/或HMG-CoA还原酶相关疾病的方法。特别地，本发明提供了用于通过抑制p38α MAP激酶和/或HMG-CoA还原酶来治疗动物主体的炎症和/或心血管疾病的物质组成，以及提供这些物质组成的配方和给药方式。本发明还提供了用于有理设计MAP激酶、HMG-CoA还原酶或两者的抑制剂以用于本发明实践的方法。
• THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS
  申请人：BROWN Dennis M.

  公开号：US20160045502A1

  公开（公告）日：2016-02-18

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to mustard-based alkylating agents such as uracil mustard and analogs, derivatives, or prodrugs thereof, including 6-methyluracil mustard and 6-ethyluracil mustard.

  本发明描述了一种改善先前受到治疗性能不佳限制的治疗剂的治疗效果的方法和组合物，通过改善单药疗法的功效或减少副作用。这种方法和组合物特别适用于芥子碱基烷基化剂，例如尿嘧啶芥和其类似物、衍生物或前药，包括6-甲基尿嘧啶芥和6-乙基尿嘧啶芥。
• Novel compositions and methods for treating hyperproliferative diseases
  申请人：Chen, Chien-Hung

  公开号：EP2123267A1

  公开（公告）日：2009-11-25

  The invention relates to a composition that includes a first agent selected including an agent that possesses anti-inflammatory activity or acetaminophen, phenacetin, tramadol and the like; a second agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5-monophosphate-activated Protein kinase (AMPK) activator; a third agent that possesses or maintains serotonin activity.

  本发明涉及一种组合物，其中包括第一种药剂，选自具有抗炎活性的药剂或对乙酰氨基酚、苯乙哌啶、曲马多等；第二种药剂，选自氧化磷酸化抑制剂、离子贮存剂和腺苷-5-单磷酸激活蛋白激酶（AMPK）激活剂；第三种药剂，具有或保持血清素活性。
• Novel composition for treating metabolic syndrome
  申请人：IPINTL, LLC

  公开号：EP2494967A1

  公开（公告）日：2012-09-05

  The invention relates to a composition that includes a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5'-monophosphate-activated Protein kinase (AMPK) activator; a second agent that possesses anti-inflammatory activity; and a third agent that possesses serotonin activity.

  本发明涉及一种组合物，其中包括选自氧化磷酸化抑制剂、离子贮存剂和腺苷-5'-单磷酸激活的蛋白激酶（AMPK）激活剂组成的组的第一种药剂；具有抗炎活性的第二种药剂；以及具有血清素活性的第三种药剂。